Genetic Technologies Limited (NASDAQ:GENE) Short Interest Up 48.0% in October

Genetic Technologies Limited (NASDAQ:GENE) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 25,900 shares, a growth of 48.0% from the October 15th total of 17,500 shares. Based on an average daily volume of 15,700 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Trading of Genetic Technologies

An institutional investor recently bought a new position in Genetic Technologies stock. BNP Paribas Financial Markets acquired a new stake in Genetic Technologies Limited (NASDAQ:GENE) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 9,100 shares of the biotechnology company’s stock, valued at approximately $26,000. BNP Paribas Financial Markets owned 0.24% of Genetic Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 0.63% of the company’s stock.

Genetic Technologies Price Performance

GENE stock remained flat at $0.77 during mid-day trading on Friday. Genetic Technologies has a 12 month low of $0.67 and a 12 month high of $3.77. The company’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $1.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.88 and a quick ratio of 0.83.

Genetic Technologies Company Profile

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments.